(HG-ESS).
LG-ESS frequently occurs before menopause. The prognoses of LMS and HG-ESS are extremely poor. 3 With the recent developments in genomic analysis techniques, the pathogenesis of these tumors has been becoming clearer, and some biomarker candidates have appeared. In the present article, the development and pathological states of uterine sarcoma (u-LMS and ESS) are described based on findings from genomic analysis, and some molecular biomarker candidates for diagnosis and prognosis are discussed.
| UTERINE LEIOMYOSARCOMA
Soft tissue sarcomas have been traditionally classified by their location of occurrence. However, based on the development of genomic analysis in the last few years, a new concept has arisen that STS can be divided into 2 groups. One, which accounts for one-third of STS, is a relatively simple tumor and has a diploid karyotype with several chromosome abnormalities. The other, which accounts for two-thirds of STS, has a complicated karyotype, with instability of many genes and mutation of the TP53 gene that encodes p53 in many cases; 4 u-LMS is considered to belong to the latter group. Moreover, u-LMS demonstrates complicated tumor development and pathology that differs from LMS originating from other sites due to the involvement of estrogen. 
. 4 In addition, whole-exome sequencing of soft tissue LMS and u-LMS has confirmed and demonstrated frequent alterations in TP53, RB1, a-thalassemia/mental retardation syndrome X-linked (ATRX) and mediator complex subunit 12 (MED12). 6, 7 Other shared features of LMS were elevated microRNA (miRNA)-143 and miRNA-145 expressions, low miRNA expressions of inflammatory response genes, and low leukocyte fraction on methylation analysis. In contrast, u-LMS and soft tissue LMS had significantly different methylation and miRNA expression signatures, with u-LMS showing a higher DNA damage response score and hypomethylation of estrogen receptor 1 (ESR1) target genes, while soft tissue LMS had a more prominent hypoxia inducible factor (HIF) 1a signaling signature, suggesting that the use of different management approaches should be considered for u-LMS and soft tissue LMS due to the predicted differences in hormonal responsiveness and stress responses. 4 
| Whole molecular mechanisms of tumor development, metastasis and chemoresistance in leiomyosarcoma
To elucidate the molecular mechanisms of tumor development and metastasis, numerous experimental animal models have been created.
Hernando et al found a defect in the PI3K-AKT signal transduction pathway in many LMS. They succeeded in creating smooth muscle cell-specific Pten knockout animals (Tagln-Cre; Ptenflox/flox). This mouse model showed smooth muscle cell hyperplasia and abdominal LMS. However, development of LMS was not observed in the uterus and in lung metastases. 8 Xing et al introduced Cre recombinase into the anti-Mullerian hormone type II receptor (Amhr 2) locus in mice to conditionally inactivate p53 in the reproductive tract and reported that u-LMS developed in 50% of the mice within 13 months. Furthermore, when the tumor suppressor gene BRCA1 was also inactivated, the frequency of tumor development increased to 82%. 9 Strizzi et al reported that Cripto-1 (CR-1) protein, an active growth factor in the Wnt signaling pathway, is present in ≥70% of u-LMS, and they created a CR-1 overexpression transgenic mouse model. Wnt signaling and cSrc and AKT signaling pathways were activated in these mice, and u-LMS were detected in approximately 20% of the mice. These findings suggested that crosstalk between the Wnt signaling pathway and the Src/AKT pathway may play a significant role in the development of u-LMS. Interestingly, p53 mutation was not involved in the development of u-LMS in these animals. 10 Kawabe et al developed a uterine sarcoma tissue-derived orthotopic and metastatic mouse model using a green fluorescent protein stably expressed uterine sarcoma cell. They also identified the differential expression of genes related to cell proliferation and migration (TNNT1, COL1A2 and ZIC1) between orthotopic tumors with high and low metastatic potential. 11 Animal models are indispensable tools for the study of u-LMS because a real clinical sample makes large-scale analysis of human samples challenging.
Doxorubicin is one of the key drugs in the treatment of u-LMS, although resistance is the major hurdle, with a response rate of only 19% due to drug resistance. 12 Overcoming resistance to chemotherapy and investigating molecular targeted therapies are challenges.
Currently, multi drug resistant 1 (MDR1) is frequently associated with the overexpression of membrane-embedded drug efflux transporters, such as ATP-binding cassette transporters, known as P-glycoprotein 1 (P-gp) (also named ABCB1 ([TP-binding Cassette Sub-family B
Member 1]), leading to the reduced accumulation of chemotherapeutic drugs and chemoresistance in LMS cells. 13 expression. 14 Lin et al reported on the important role of progesterone receptor membrane component 1 (PGRMC1) encoded by PGRMC1, which is an adapter protein mediating cholesterol synthesis, steroid signaling and cytochrome p450 activation. PGRMC1 promoted cell proliferation and cell cycle progression to the S phase by mediating ERK activation, leading to doxorubicin-resistance in LMS cells. 15 In the last decade, several anticancer drugs or multityrosine kinase inhibitors have demonstrated efficacy with respect to progression-free survival and overall survival, particularly the tyrosine kinase inhibitor (TKI) pazopanib in the treatment of u-LMS. 16 However, the biological mechanisms or optimal predictive biomarkers for these therapies are still being explored. The further development of in vitro or in vivo models using advanced genetic techniques will continue to increase our understanding of LMS biology. in the peritoneal cavity. In addition, mTOR inhibitor suppressed tumor growth. 17 Thus, the PTEN-PI3K/AKT-mTOR pathway can play important roles in not only the generation of LMS but also in the treatment and prediction of the prognosis of patients with LMS. 18, 19 However, this pathway has not been well investigated in u-LMS.
Loss at the 13q region leads to inactivation of the tumor suppressor RB1 gene. The RB1 gene is involved in the cell cycle, specifically at the G1-S phase checkpoint. Regulatory aberration at this region is known to induce cells to divide indefinitely. Dei-Tos et al 20 observed defects in RB-cyclin D1 signaling (RB1, CDKN2A which encodes p16, CCND1 which encodes cyclin D1, and CCND3 which encodes cyclin D3) in ≥90% of u-LMS patients. It has also been reported that an abnormality in this pathway is an obvious factor related to poor prognosis. 17 Many studies have shown that the frequencies of TP53 mutation in uterine leiomyoma (u-LM), smooth muscle tumor of uncertain malignant potential (STUMP) and u-LMS are 0%, 6%-29% and 24%-30%, respectively. It has also been reported that the frequencies of PTEN mutation are 5%, 33% and 42%-58%, respectively. 21 However, u-LMS has shown a lower frequency of TP53 mutation, higher expression of MDM2, and a higher TP53/MDM2 ratio than the other sarcomas.
| Genes related to the cell cycle
In general, it is difficult to distinguish between u-LM and u-LMS with protein expressions related to the cell cycle (p16, p21, p27, p53, Ki-67 and PHH3). 22 In 2004, Quade et al investigated 4 normal uterine myometrium samples, 7 u-LM and 9 u-LMS using microarrays of
In the recurrent focal copy-number alterations, the ratios of deletions of the tumor suppressors (A) and mutations (B) of TP53, RB1 and PTEN to each whole gene in leiomyosarcoma. oligonucleotides representing approximately 7000 unique probe sets.
They reported that, while there was a difference in CDKN1A, which encodes p21, which is involved in cell proliferation and the cell cycle, this difference was not significant. Moreover, they reported that there were no clear differences in cellular gene expressions between LMS that developed in the uterus vs other tissues. 23 pathways. 26 Interestingly, in vitro study of u-LM has shown that the u-LM cells with MED12 mutation grow poorly in culture and cannot be maintained through passage. 27 In 2012, the same research group demonstrated that, albeit at low frequencies, MED12 mutations are observed in u-LMS, as well as u-LM, while no mutations were found in other sarcomas or in gastrointestinal stromal tumors (GIST), suggesting that a subgroup of u-LMS may develop from an LM precursor. Furthermore, they report that such u-LMS do not have greater malignancy than those from the group without mutations. 28 In 2012, P erot et al compared MED12 protein expression between benign and malignant smooth muscle tumors. They postulated that MED12 could be a tumor suppressor gene, and that MED12 protein expression inhibits LMS oncogenesis. 29 Schwetye et al compared the frequencies of MED12 gene mutations among normal myometrium adjacent to LM, pelvic LM and extrauterine LM. MED12 mutations were detected in 54% of u-LM, 15% of cases in myometrium adjacent to LM, and 0% of extrauterine LM. Moreover, MED12 mutations were also detected in 30% of u-LMS compared with 4% of extrauterine LMS, suggesting that smooth muscle tumors in pelvic/retroperitoneal sites are subject to the same mutational changes as those of uterine myometrium. (Table 1) . 21 Bertsch et al 31 showed other genetic abnormalities in u-LM. The overexpression of high-mobility group AT-hook 2 (HMGA 2), which is an oncogene, occurred in u-LM (40%) and u-LMS (25%) with no Based on several studies, MED12 mutation is also observed in u-LMS, while it is more frequent in u-LM than in u-LMS. MED12 mutations are rarely observed in other sarcomas or in GIST, as well as extrauterine LMS, 29, 30 suggesting that MED12 can be a useful biomarker to diagnose uterine-derived LMS, although it is difficult to distinguish between u-LM and u-LMS only by examination of MED12 mutation. IMP3 encoded by IMP3 is an RNA-binding carcinoembryonic protein consisting of 580 amino acids that is observed only in advanced tumor tissues, but not in normal tissues. 36 Strong expression of IMP3 is observed in the cytoplasm in more than 50% of u-LMS cases, while it is not observed in typical u-LM. 36 Yasutake et al 37 reported a multivariate analysis that showed that advanced stage and IMP3 are independent predictors of a poor prognosis in u-LMS. 
| MicroRNA (miRNA)-181b
The Cancer Genome Atlas indicated that high miR-181b was more common in u-LMS and was an independent predictor of recurrencefree survival in a multivariate model, including tumor size. MiR-181b expression has been reported to promote proliferation and migration of vascular smooth muscle via the PI3K pathway. 4 
| KIT expression
Raspollini et al 40 showed a high frequency of positive immunostaining for KIT in u-LMS. However, imatinib is not theoretically applicable for u-LMS or ESS because of the lack of KIT hotspot mutations. 41 Pazopanib inhibits VEGF, PDGFR, FGFR and c-KIT.
After a recent successful placebo-controlled phase III trial, the PAL- 
| Molecular biomarker candidates for diagnosis and prognosis of metastases of uterine leiomyosarcoma
Recently, some researchers reported extremely interesting studies. 11, 43, 44 They investigated the gene expression patterns of primary and metastatic lesions in patients and in vivo with distant metastatic u-LMS, and they identified genes that were overexpressed in each type of lesion. Several genes, which are listed along with their functions in Table 2 , are overexpressed at primary lesion sites, and the following genes were overexpressed or down underexpressed in metastatic lesions.
Increasing evidence of intratumor genetic heterogeneity (ITH) is emerging, both within individual tumor biopsies and spatially separated between biopsies of the same tumor. Furthermore, sequential analysis of tumors has also provided evidence that ITH evolves during the course of the disease. 45 However, these genes may be useful in elucidating the mechanism of metastasis from u-LMS.
| ENDOMETRIAL STROMAL SARCOMA
Endometrial stromal sarcoma (ESS) is composed of cells similar to the endometrial stroma at the proliferative phase. Basically, it is diagnosed by histopathological criteria. The growing evidence provided by molecular genetic analysis has been increasingly used to diagnose ESS (Table 3 ) (Figure 2 ). translocation t(7;17) (p15;q21); 6p21-rearrangements; and X;22 or 17-rearrangements.
Chromosomes 7 and 17 are recombined in the first genetic hallmark to be discovered in ESS; namely, the translocation t(7;17) (p15; q21). Two zinc finger genes, the JAZF1 gene from chromosomal band 7p15 and SUZ12 (formerly JJAZ1) from 17q11, are fused by this translocation. 50 Subsequent studies have shown that the fusion of JAZF1 and SUZ12 is recognized in almost all ESS cases and is more frequently expressed in LG-ESS than in HG-ESS. 51 Micci et al 52 show that the PHD finger protein 1 (PHF1) gene from chromosomal band 6p21 recombined with JAZF1 as the partner gene of the JAZF1 gene in LG-ESS. Further studies have shown that the PHF1 gene from chromosomal band 6p21 recombined with JAZF1, EPC1, MEAF6 or BRD8, which encode the proteins involved in regulation of protein acetylation and/or histone acetyltransferase activity. 53 All these fusions in ESS combined genes are involved in transcriptional regulation; that is, polycomb group complex-mediated aberration methylation/acetylation; hence, their presumed oncogenic effects may be involved in the pathogenesis of ESS. 52 Currently, ESS is considered to be a tumor with molecular genetic heterogeneity in gene rearrangement. Representative fusion
Functions References
Overexpressed gene at primary lesion site 
SGK1
A factor involved in the activation of ion channels for the transport of K, Na and cellular signal transduction of serine/threonine kinases.
Davidson et al has shown high sensitivity and specificity in LG-ESS and HG-ESS. 61 3.5 | Molecular biomarkers for metastases of endometrial stromal sarcoma
In 2013, it was first reported that an LG-ESS case with a PHF1-JAZF1 fusion gene in the metastatic lesion, as well as the primary lesion, had invasive progression and fatal lung metastasis. 62 It has also been reported that an LG-ESS case with JAZF1 rearrangement and MDM2 amplification had lethal lung metastasis. 60 On the other hand, it has been reported that a case with the JAZF1-SUZ12 fusion gene in the primary and metastatic lesion had metastatic but not invasive disease. 63 It has been reported that an HG-ESS case with metastasis with YWHAE rearrangement responded to anthracycline-based therapy and showed relatively long-term survival. 64 These facts indicate that further study to elucidate the relationship between the pattern of fusion genes and the prognosis or therapeutic effects in ESS is needed in the future.
| CONCLUSION S
Further advances in genome analysis are expected to elucidate not only the pathogenic genes but also the molecular basis of various abnormal traits, such as metastasis, for uterine sarcoma, which is characterized by its rarity and diversity. The development of molecular imaging methods or molecular targeted drugs based on these findings is also expected in the future. 
